Two Case Reports of Type 2 Diabetes Induced by Immune Checkpoint Inhibitors
Combined with Chemotherapy.
10.3779/j.issn.1009-3419.2022.102.10
- Author:
Ping XIAO
1
;
Linlin ZHANG
1
;
Yu WANG
2
;
Fanlu MENG
1
;
Xin WANG
1
;
Diansheng ZHONG
1
Author Information
1. Department of Medical Oncology,
Tianjin Medical University General Hospital, Tianjin 300052, China.
2. Department of Medical Endocrine Metabolism,
Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Journal Article
- Keywords:
Adverse reaction;
Immune checkpoint inhibitors;
Type 2 diabetes mellitus
- MeSH:
Diabetes Mellitus, Type 2/drug therapy*;
Humans;
Immune Checkpoint Inhibitors;
Immunotherapy/adverse effects*;
Lung Neoplasms/therapy*;
Molecular Targeted Therapy
- From:
Chinese Journal of Lung Cancer
2022;25(4):287-290
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) have become an important means of cancer treatment, and their application in the clinic is becoming more and more widespread. The adverse reactions caused by ICIs are gradually recognized. Among them, immunotherapy-related diabetes is a rare adverse reaction and type 1 diabetes mellitusis common. With the wide application of ICIs combined with chemotherapy in lung cancer patients, patients with type 2 diabetes mellitus have gradually been discovered during the treatment. However, the effect of continued use of ICIs maintenance therapy on blood glucose and ICIs treatment process in these patients is still unclear. This article reports two cases of type 2 diabetes mellitus induced by immune checkpoint inhibitor combined with chemotherapy, one of whom converted to type 1 diabetes mellitus, in order to increase the understanding of immunotherapy-related diabetes.
.
